Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

M-40403 Metaphore Pharmaceuticals.

Mario Di Napoli1, Francesca Papa

  • 1Neurological Section, SMDN-Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, Via Trento 41, I-67039-Sulmona (AQ), Italy. mariodinapoli@katamail.com

Idrugs : the Investigational Drugs Journal
|January 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of Adenosine A1/A3 Receptors Agonist on Improving the Outcomes of TBI and Stroke: Focus on AST-004.

Current neurology and neuroscience reports·2026
Same author

Impact of Mandibular Advancement Therapy on Occlusal Plane Orientation and Incisor Inclination in Obstructive Sleep Apnea Patients: A Retrospective Observational Study.

Journal of clinical medicine·2025
Same author

On Neurocardiology Updates: an Interdisciplinary Field at the Intersection of Neurology and Cardiology.

Current neurology and neuroscience reports·2025
Same author

Interleukin-6 and its association with outcome in traumatic brain injury: a prospective cohort.

Scandinavian journal of trauma, resuscitation and emergency medicine·2025
Same author

Traumatic Brain Injury and Gut Microbiome: The Role of the Gut-Brain Axis in Neurodegenerative Processes.

Current neurology and neuroscience reports·2025
Same author

Trends in Ischemic Stroke Hospitalization and Outcomes in the United States Pre- and Peri-COVID-19 Pandemic: A National Inpatient Sample Study.

Journal of clinical medicine·2025

Metaphore Pharmaceuticals is developing M-40403, a novel superoxide dismutase mimetic, for treating pain, inflammation, and dermatological conditions. This compound also shows potential in mitigating side effects from chemotherapy and radiation therapy.

Area of Science:

  • Pharmacology and Therapeutics
  • Biochemistry

Background:

  • Superoxide dismutase (SOD) plays a crucial role in cellular defense against oxidative stress.
  • Mimicking SOD activity is a therapeutic strategy for conditions involving excessive reactive oxygen species.

Purpose of the Study:

  • To evaluate M-40403, a novel superoxide dismutase mimetic, for therapeutic applications.
  • To explore the potential of M-40403 in managing pain, dermatological diseases, and inflammation.
  • To investigate M-40403 for its efficacy in treating side effects of chemotherapy and radiation therapy.

Main Methods:

  • Preclinical studies involving M-40403 administration.
  • Assessment of M-40403's efficacy in models of pain, inflammation, and dermatological conditions.
  • Evaluation of M-40403's impact on chemotherapy- and radiation-induced side effects.

Related Experiment Videos

Main Results:

  • M-40403 demonstrates potential as a superoxide dismutase mimetic.
  • The compound shows promise in preclinical models for pain, inflammation, and dermatological disease treatment.
  • Preliminary investigations suggest M-40403 may alleviate treatment-related side effects.

Conclusions:

  • M-40403 represents a promising therapeutic candidate targeting oxidative stress.
  • Further research is warranted to establish M-40403's clinical utility in pain, inflammation, and oncology support.
  • The development of M-40403 could offer new treatment avenues for various inflammatory and pain conditions.